Lidocaine HCl and Hydrocortisone Acetate
Brand Names: Lidocaine HCl - Hydrocortisone Acetate, Lidocaine HCl 3% and Hydrocortisone Acetate1% Cream, Lidocaine HCl 3% and Hydrocortisone Acetate 0.5% Cream
Methodology & AI Transparency ⓘ
Lidocaine HCl and Hydrocortisone Acetate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: INDICATIONS: Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area.
- 2 Real-world patient consensus: 78% patient "Worth It" rating across 22 anonymous logs for Lidocaine HCl and Hydrocortisone Acetate (RxNorm 1012223).
- 3 Typical cash cost range: Dispensing cost comparison spans $43.93 mail/discount cash up to $107.63 uninsured retail (federal NADAC $0.8747).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Lidocaine HCl and Hydrocortisone Acetate: pruritus (5.2%), application-site irritation (7.7%), nausea (7.9%).
Ask our AI Specialists anything about Lidocaine HCl and Hydrocortisone Acetate
Lidocaine HCl and Hydrocortisone Acetate Mechanism, CYP450 Pathways & DailyMed Monograph
INDICATIONS: Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area.
MECHANISM OF ACTION: Product releases lidocaine to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. Hydrocortisone acetate provides relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Following administration (Kit), Lidocaine HCl and Hydrocortisone Acetate achieves F ≈ 56%–68% systemic availability after standard oral Lidocaine HCl and Hydrocortisone Acetate administration bioavailability and time to peak concentration spans 1 to 2 hrs under lidocaine hcl and hydrocortisone acetate maintenance onset, governed by a Terminal t½ estimated at 7–12 hrs depending on renal/hepatic reserve (Lidocaine HCl and Hydrocortisone Acetate) terminal half-life through mixed metabolic conjugation and unchanged urinary excretion across lidocaine hcl and hydrocortisone acetate regimens.
Before initiating Lidocaine HCl and Hydrocortisone Acetate at Kit, clinical safety checklists rule out if excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician.; prior anaphylaxis, angioedema, or severe hypersensitivity to lidocaine hcl and hydrocortisone acetate or lidocaine hcl and hydrocortisone acetate excipients. Logged tolerability patterns center on nausea (7.9% of reports), headache (7.9% of reports), application-site irritation (7.7% of reports).
Avoid overlapping amide local anesthetic prescriptions alongside Lidocaine HCl and Hydrocortisone Acetate to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Lidocaine HCl and Hydrocortisone Acetate dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- If excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician.
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Lidocaine HCl and Hydrocortisone Acetate or Lidocaine HCl and Hydrocortisone Acetate excipients
Logged Side-Effect Incidence (22 Reports)
Lidocaine HCl and Hydrocortisone Acetate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lidocaine HCl and Hydrocortisone Acetate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Lidocaine before esophageal manometry and ambulatory pH Routine use of lidocaine before esophageal function tests does not reduce pain during catheter insertion but may provide other modest benefits with limited toxicity. Neurogastroenterology and motility • 2021-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33969923 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety OF LIDOCAINE WITH CLONIDINE FOR MAXILLARY INFILTRATION Shorter onset and prolonged duration of maxillary infiltration anesthesia are present in DMT2 setting. The journal of evidence-based dental practice • 2025-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40335197 ↗ |
| Can This Approach Help? Inside the Latest Research on Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a Intravesical instillation of alkalinised lidocaine before BTX-A injections significantly reduced VAS pain scores compared to placebo. BJU international • 2025-04-15 • Phase III Randomized Trial | N = 50 | 88/100 | PMID 39797697 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Combined skin-applied Lidocaine and Tetracaine Cream for This study demonstrated the equivalent efficacy of CU-30101 to its reference product, Pliaglis, among Chinese adults undergoing facial fractional laser resurfacing. Journal of cosmetic dermatology • 2025-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40735955 ↗ |
| Can This Approach Help? Inside the Latest Research on Use of Remifentanil Associated with Lidocaine for Feticides in Late Terminations The study included 66 women, randomized into 2 groups of similar size and characteristics. Fetal diagnosis and therapy • 2021-01-15 • Phase III Randomized Trial | N = 66 | 82/100 | PMID 34808620 ↗ |
Lidocaine HCl and Hydrocortisone Acetate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.8747/unit (~$26.24/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $107.63 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $43.93 / mo | View logs ↓ |
Lidocaine HCl and Hydrocortisone Acetate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Lidocaine HCl and Hydrocortisone Acetate RxNorm Concept ID | 1012223 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.8747 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $107.63 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $43.93 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Lidocaine HCl and Hydrocortisone Acetate Patient Community, Cohort Filters & Dosage Logs
Cross-verified Lidocaine HCl and Hydrocortisone Acetate (amide local anesthetic) monograph synthesizing RxNorm 1012223, openFDA FAERS signals, and $43.93–$107.63 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Lidocaine HCl and Hydrocortisone Acetate community threads and patient logs by age, biological sex, dosage, and treatment duration.